 |
 |

Follow-up of 89 Asymptomatic Patients With Adrenoleukodystrophy Treated With Lorenzos Oil
Hugo W. Moser, MD;
Gerald V. Raymond, MD;
Shou-En Lu, PhD;
Larry R. Muenz, PhD;
Ann B. Moser, BA;
Jiahong Xu, MS;
Richard O. Jones, PhD;
Daniel J. Loes, MD;
Elias R. Melhem, MD;
Prachi Dubey, MD, MPH;
Lena Bezman, MD, MPH;
N. Hong Brereton, MS, RD;
Augusto Odone
Arch Neurol. 2005;62:1073-1080.
Objectives To identify asymptomatic boys with X-linked adrenoleukodystrophy who have a normal magnetic resonance image (MRI), and to assess the effect of 4:1 glyceryl trioleateglyceryl trierucate (Lorenzos oil) on disease progression.
Method Eighty-nine boys (mean ± SD baseline age, 4.7 ± 4.1 years; range, 0.2-15 years) were identified by a plasma very long-chain fatty acids assay used to screen at-risk boys. All were treated with Lorenzos oil and moderate fat restriction. Plasma fatty acids and clinical status were followed for 6.9 ± 2.7 years. Changes in plasma hexacosanoic acid levels were assessed by measuring the length-adjusted area under the curve, and a proportional hazards model was used to evaluate association with the development of abnormal MRI results and neurological abnormalities.
Results Of the 89 boys, 24% developed MRI abnormalities and 11% developed both neurological and MRI abnormalities. Abnormalities occurred only in the 64 patients who were aged 7 years or younger at the time therapy was started. There was significant association between the development of MRI abnormalities and a plasma hexacosanoic acid increase. (For a 0.1-µg/mL increase in the length-adjusted area under the curve for the hexacosanoic acid level, the hazard ratio for incident MRI abnormalities in the whole group was 1.36; P = .01; 95% confidence interval, 1.07-1.72.) Results for patients aged 7 years or younger were similar (P = .04).
Conclusions In this single-arm study, hexacosanoic acid reduction by Lorenzos oil was associated with reduced risk of developing MRI abnormalities. We recommend Lorenzos oil therapy in asymptomatic boys with X-linked adrenoleukodystophy who have normal brain MRI results.
Author Affiliations: Kennedy Krieger Institute and Departments of Neurology and Pediatrics, Johns Hopkins University, Baltimore, Md (Drs H. W. Moser, Raymond, A. B. Moser, Jones, Dubey, and Bezman); Division of Biometrics, University of Medicine and Dentistry of New Jersey, Piscataway (Dr Lu); Westat, Rockville, Md (Drs Muenz and Xu); Suburban Radiological Consultants Ltd, Minneapolis, Minn (Dr Loes); Department of Radiology, University of Pennsylvania, Philadelphia (Dr Melhem); General Clinical Research Center, Johns Hopkins School of Medicine, Baltimore (Dr Brereton); and Myelin Project, Dunn Loring, Va (Mr Odone).
RELATED ARTICLE
Lorenzos Oil: Advances in the Treatment of Neurometabolic Disorders
Raymond Ferri and Phillip F. Chance
Arch Neurol. 2005;62(7):1045-1046.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Hugo W. Moser, MD (1924-2007)
Raymond
Arch Neurol 2007;64:758-759.
FULL TEXT
Uptake and metabolism of plasma-derived erucic acid by rat brain
Golovko and Murphy
J. Lipid Res. 2006;47:1289-1297.
ABSTRACT
| FULL TEXT
Cognitive Evaluation of Neurologically Asymptomatic Boys With X-linked Adrenoleukodystrophy
Cox et al.
Arch Neurol 2006;63:69-73.
ABSTRACT
| FULL TEXT
Adrenoleukodystrophy: New Approaches to a Neurodegenerative Disease
Moser et al.
JAMA 2005;294:3131-3134.
ABSTRACT
| FULL TEXT
|